Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have multiple myeloma that has come back after treatment and is no longer responding to treatment, with signs of the disease that can be measured and tracked.
- People who have already been through at least 3 previous rounds of treatment for their myeloma, including specific types of drugs known as proteasome inhibitors, immunomodulatory drugs, and a CD38-targeting antibody therapy (confirm with trial site for exact drugs that count).
- People who are generally well enough to carry out everyday activities with little to no limitation, as measured by a standard medical scale called the ECOG score of 0 or 1.
- People whose blood and other lab test results fall within the ranges set out by the trial protocol (confirm with trial site for specific values).
Who may not be able to join:
- People whose myeloma has spread to the brain or spinal cord.
- People who have been diagnosed with certain related blood or plasma cell conditions, including plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or primary light chain amyloidosis.
- People who currently have an active, serious infection that requires treatment with antimicrobial medicines.
- People who need to take steroid medicines regularly for any ongoing health condition.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 617-223-7349
Australian sites
+61 2 9515 5721
+61 3 8559 7851
+61 3 9076 2000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence and severity of treatment-emergent adverse events (TEAEs), including dose-limiting toxicities (DLTs), and/or establish the recommended Phase 2 Dose
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.